Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine
نویسندگان
چکیده
منابع مشابه
Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine
The candidate vaccine HZ/su is being developed to prevent herpes-zoster disease (HZ). HZ occurrence is attributed to declines in varicella-zoster virus (VZV) specific T-cell immunity. HZ/su contains VZV antigen, gE, and Adjuvant System AS01B (liposome-based formulation of MPL and QS-21). In clinical trials, AS01B enhances CD4+ T-cell responses to gE. In clinical trials of other vaccines, Adjuva...
متن کاملSafety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su)
An adjuvanted recombinant subunit candidate vaccine (HZ/su) containing varicella zoster virus envelope glycoprotein E was developed for the prevention of herpes zoster and its complications. This study evaluated safety and reactogenicity of HZ/su in an ethnic Japanese population. This was a phase I, open-label and single-center study conducted between March and November of 2010 in Australia. Tw...
متن کاملAdjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
n engl j med 373;16 nejm.org october 15, 2015 1575 Observations from each trajectory are also interesting (Table 1). An FEV1 that is normal at cohort inception without COPD at the final examination (trajectory 1) seems reasonable. An FEV1 that is normal or low at cohort inception with concomitant COPD at the final examination (trajectories 3 and 4) does also, especially considering the authors’...
متن کاملVaccine against herpes zoster
The herpes zoster vaccine is made using high doses of live attenuated varicella/zoster virus. The vaccine is well tolerated and has few adverse effects: the most common one is pain at the injection site. Complications can occur mainly in persons who had prior zoster keratitis or uveitis. The vaccine can prevent this disease with low mortality but high morbidity.
متن کاملHerpes zoster vaccine in Korea
Herpes zoster and post-herpetic neuralgia deteriorate the quality of life because of severe pain and complications, and cause considerable social and economic burden of disease. In 2012, herpes zoster vaccine was released in Korea. The efficacy of herpes zoster vaccine is known to be 51.3-66.5% among the aged over 60 and 69.8-72.4% among adults between 50 and 59. It is also known that preventiv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Human Vaccines & Immunotherapeutics
سال: 2016
ISSN: 2164-5515,2164-554X
DOI: 10.1080/21645515.2016.1154247